He et al (2019) revealed that TSA, an HDAC inhibitor, decreased the EGFR-Arf1 signaling to inhibit cell migration and invasion in SCCHN. Citro et al (2019) demonstrated that SAHA, in combination with gefitinib, displayed synergistic anti-tumor activities in SCCHN cell lines via disturbing EGFR receptor expression. This evidence concerns the gene HDAC9 and neoplasm.